PRESS RELEASE
View printer-friendly version << Back
WNS Extends Contract with GSK to Provide High-end Analytical Services
“We are extremely proud to renew our agreement with GSK. For more than a
decade, WNS has been a trusted partner driving evidence-based decisions
through high-end research and analytics services. Under the agreement
with GSK, WNS has set up a dedicated state-of-the-art Knowledge Center,
driven by a team of over 600 industry experts. WNS leverages its deep
Pharma domain knowledge, robust analytics capabilities and proprietary
frameworks to deliver actionable business insights to GSK,” said
With a team of over 2,500 research and analytics professionals globally, WNS provides a wide range of analytics services to our clients across Big Data, marketing, digital, HR, and operations. These solutions leverage WNS’ deep domain expertise, proprietary frameworks and technology-enabled capabilities.
About WNS
Safe Harbor Provision
This document includes information which may constitute forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, the accuracy of which are
necessarily subject to risks, uncertainties, and assumptions as to
future events. Factors that could cause actual results to differ
materially from those expressed or implied are discussed in our most
recent Form 20-F and other filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160304005243/en/
Source:
WNS (Holdings) Limited
Investors:
David
Mackey
Corporate SVP - Finance & Head of Investor Relations
+1
(201) 942-6261
david.mackey@wns.com
or
Media:
Archana
Raghuram
Head – Corporate Communications
+91 (22) 4095 2397
archana.raghuram@wns.com;
pr@wns.com